ERBB2 and breast carcinoma: Collectively, these findings demonstrate that CTTN enhances CSC activity and induces trastuzumab resistance, suggesting that CTTN is a possible oncogenic driver and a potential target for overcoming trastuzumab resistance in HER2+ breast cancer.